BioLight seeks FDA IND authorization for subconjunctival Latanoprost controlled release insert Phase We/IIa study BioLight Israeli Lifestyle Sciences Investments Ltd. , a company that invests in, manages and commercializes biomedical improvements grouped into clusters around described medical ailments, announces that ViSci, its owned subsidiary wholly, provides filed an Investigational New Medication program with the U info http://www.buycialisgenericonline.biz .S. Food and Medication Administration to carry out a Stage I/IIa clinical study using its subconjunctival Latanoprost managed release insert for the treating glaucoma. Related StoriesEnvisia's ENV515 meets principal efficacy endpoint in stage 2a glaucoma trialAllergan completes acquisition of AqueSysLatinos with African ancestry in higher risk for glaucoma The 3-month research in 68 glaucoma individuals is made to prove the basic safety and efficacy of different dosages of the put in containing its proprietary type of Latanoprost.